Every figure below is our model's own output โ forward-simulated and gradient-verified, with limits stated. Letter grades appear only where the reference carries a documented uncertainty; where it does not, the figure is marked unscored rather than given a letter. Self-correcting agentic research.
๐งซ
JCVI-syn3A minimal cell
Differentiable whole-cell of the smallest genome (493 genes); it replicates & divides.
cell cycle replicates & dividesnot scored
No fitting. Prototype; deterministic, not 4D-stochastic.
๐ฆ
E. coli โ Min oscillation
Pole-to-pole protein wave that sets the division site; a differentiable spatial pattern.
period 41.7 s in 40โ120 s rangeA
Published model, not re-fit. Mean-field, not stochastic.
๐ง
Human disease โ protein aggregation
Differentiable neurodegeneration aggregation cascades (Alzheimer-type), with mechanism-based screening.
validated vs published kinetics A
Parameter-free scaling law reproduced (no fit); mechanism-plausibility, not efficacy.
๐ฏ
Drug mechanism screening
Gradients rank which molecular step a therapy must hit โ and flag counterproductive ones โ across our disease models.
โ(outcome)/โ(mechanism) FD-verified
Capability shown on public targets; effects are uncertainty bands, not efficacy. Specific compounds & targets are private.
๐ซ
Genome-scale human metabolism
Differentiable human liver metabolism on a genome-scale reconstruction (~10,600 reactions); fatty-liver phenotype emerges from mass balance.
genome-scale ~10,600 reactionsdirectional
Constraint-based metabolism, not a whole cell; pinpoints the highest-leverage disease step.
๐ฐ๏ธ
Universal clock (reproduction)
Reproduced the equant "universal dynamical clock" method; verified on a Kepler orbit.
31,531ร more uniform null on ours
Null result: no gain on our symmetric oscillators. Core reproduced, not the full paper.
๐ซ
Lung โ fibrosis tipping point
A bistable switch explaining why fibrosis becomes progressive & self-sustaining; differentiable drug-lever contrast (reversal vs prevention).
bistable + hysteresis A
Published-mechanism model; drug effects are bands, not efficacy.
๐ซ
Heart โ HFpEF energetics
The failing heart as an "engine out of fuel": energy reserve (PCr/ATP) drops and collapses under stress.
reserve collapse A
Metabolism only (no electrophysiology); mechanism-plausibility.
๐ง
Brain โ metabolism โ tau circuit
Glucose hypometabolism โ protein-modification stress โ tau, integrated into one mechanism circuit linking energy to neurodegeneration.
integrated circuit A
Causality debated; coupling is a labelled assumption (band).
๐ซ
Gut โ axis hub
Enterocyte metabolism + leaky-gut bistability; quantifies gutโliver & gutโbrain signals that connect the organs.
gut-liver-brain axes A
Not a microbiome ecosystem; axis couplings are bands.
๐ซ
Kidney โ CKD (metabolicโfibrosis)
A tubular fatty-acid-oxidation defect lowers the fibrosis threshold; the metabolic lever can reverse it.
metabolic driver A
Reuses the fibrosis switch; drug effects are bands.
๐ฅ
Pancreas โ T2D + direction check
Beta-cell glucoseโinsulin, plus a check that caught a wrong-direction drug mechanism โ which binding/docking alone cannot see.
wrong-direction caught A
Mechanism-plausibility; context-dependent (band), not clinical.
๐ฉธ
Blood & immune
RBC oxygen metabolism + macrophage inflammation โ grounds the systemic inflammation shared across every organ model.
grounds inflammation A
Two cell types, not the whole immune system; bands.
๐
Connected human โ whole-body integration
All 7 organs coupled through a shared bloodstream + physiological axes: a perturbation in one organ propagates body-wide, and a whole-body differentiable inverse-design ranks the best systemic intervention.
7 organs ยท 1 body A
Coarse mechanism coupling โ NOT a complete human, not PK/PD; self-flags where it doesn't match clinical biology.
๐ฌ
Whole-body drug trial (QSP)
Dose a drug into the whole body โ see efficacy AND off-target effects across organs at once; differentiable therapeutic-window & tissue-selectivity optimization.
efficacy-safety window A
Calibration/PK-PD prototype; mechanism bands, not a clinical/safety prediction.
๐ฅ
In-silico virtual clinical trial
Sample the whole-body model into a virtual population (~5,000 virtual patients with individual variation) โ predict responder fraction, the responding subpopulation (biomarker), and the safety-event distribution.
responder % ยท go/no-go
Turns a candidate ranking into a development decision. Virtual-population prototype.
๐งฌ
Digital twin (personalized)
Personalize the whole body to an individual, calibrate to their data โ their own optimal therapy. The same drug helps one person but not another.
per-person optima A
Concept prototype; synthetic individuals; identifiability limits apply.